

## DAFTAR PUSTAKA

- Abedi, G., Adelman, R. A. dan Salim, S. (2013) "Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents," *Seminars in Ophthalmology*, 28(3), hal. 126–130.
- Bandello, F. *et al.* (2017) "Diabetic macular edema," *Developments in Ophthalmology*, 58, hal. 102–138.
- Barañano, D. E. *et al.* (2009) "Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation," *British Journal of Ophthalmology*, 93(10), hal. 1387–1390.
- Bracha, P. *et al.* (2018) "The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review," *Survey of Ophthalmology*. Elsevier Inc., 63(3), hal. 281–295.
- Charan, J. dan Biswas, T. (2013) "How to calculate sample size for different study designs in medical research?," *Indian Journal of Psychological Medicine*, 35(2), hal. 121–126.
- Faghihi, H. *et al.* (2017) "Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up.," *Medical hypothesis, discovery & innovation ophthalmology journal*, 6(3), hal. 67–75.
- Ghanbari, H. *et al.* (2017) "Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naïve diabetic macular edema: a randomized double-blind clinical trial," *International Ophthalmology*. Springer Netherlands, 37(4), hal. 867–874.
- Kim, S. J. *et al.* (2008) "Safety of intravitreal ketorolac and diclofenac: An electroretinographic and histopathologic study," *Retina*, 28(4), hal. 595–605.
- Kim, S. J., Doherty, T. J. dan Cherney, E. F. (2012) "Intravitreal ketorolac for chronic uveitis and macular edema: A pilot study," *Archives of Ophthalmology*, 130(4), hal. 456–460.
- Kim, T. K. *et al.* (2017) "Factors influencing intravitreal bevacizumab and triamcinolone treatment in patients with diabetic macular edema," *European Journal of Ophthalmology*, 27(6), hal. 746–750.
- Komarowska, I. *et al.* (2009) "Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits," *Retina*, 29(1), hal. 98–105.
- Lee, R. *et al.* (2018) "Factors affecting signal strength in spectral-domain optical coherence tomography," *Acta Ophthalmologica*, 96(1), hal. e54–e58.
- Lee, R., Wong, T. Y. dan Sabanayagam, C. (2015) "Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss," *Eye and Vision*. Eye and Vision, 2(1),

hal. 1–25.

- Li, X., Zarbin, M. A. dan Bhagat, N. (2017) “Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?,” *Developments in Ophthalmology*, 60, hal. 131–142.
- Lim, H. Bin *et al.* (2018) “The Importance of Signal Strength in Quantitative Assessment of Retinal Vessel Density Using Optical Coherence Tomography Angiography,” *Scientific Reports*, 8(1), hal. 1–8.
- Maldonado, R. M. *et al.* (2011) “Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation,” *Current Eye Research*, 36(8), hal. 768–773.
- Margalit, E. *et al.* (2006) “The safety of intraocular ketorolac in rabbits,” *Investigative Ophthalmology and Visual Science*, 47(5), hal. 2093–2099.
- Mesquida, M., Drawnel, F. dan Fauser, S. (2019) “The role of inflammation in diabetic eye disease,” *Seminars in Immunopathology*. *Seminars in Immunopathology*, 41(4), hal. 427–445.
- Noma, H. *et al.* (2014) “Role of inflammation in diabetic macular edema,” *Ophthalmologica*, 232(3), hal. 127–135.
- Parravano, M., Costanzo, E. dan Querques, G. (2020) “Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors,” *Acta Diabetologica*. Springer Milan, 57(8), hal. 911–921.
- Rodrigues, M. W. *et al.* (2020) “Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*. *Graefe’s Archive for Clinical and Experimental Ophthalmology*, 258(3), hal. 479–490.
- Romero-Aroca, P., Baget-Bernaldiz, M. dan Pareja-Rios, A. (2016) “Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory,” *Journal of Diabetes Research*, 2016
- Schmidt-Erfurth, U. *et al.* (2017) “Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA),” *Ophthalmologica*, 237(4), hal. 185–222.
- Schoenberger, S. D. *et al.* (2014) “Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy,” *JAMA Ophthalmology*, 132(1), hal. 32–37.
- Scholl, S. *et al.* (2011) “General pathophysiology of macular edema,” *European Journal of Ophthalmology*, 21(SUPPL.6), hal. 10–19. doi: 10.5301/EJO.2010.6050.
- Semeraro, F. *et al.* (2015) “Efficacy and vitreous levels of topical NSAIDs,” *Expert Opinion on Drug Delivery*, 12(11), hal. 1767–1782.

- Semeraro, F. *et al.* (2019) “Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications,” *Diabetes and Metabolism*. Elsevier Masson SAS, 45(6), hal. 517–527.
- Shimura, M. *et al.* (2013) “Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular EDEMA,” *Retina*, 33(4), hal. 740–747.
- Shin, S. H., Park, S. P. dan Kim, Y.-K. (2018) “Factors Associated with Pain Following Intravitreal Injections,” *Korean Journal of Ophthalmology*, 32(3), hal. 196.
- Sinha, V. R., Kumar, R. V. dan Singh, G. (2009) “Ketorolac tromethamine formulations: An overview,” *Expert Opinion on Drug Delivery*, 6(9), hal. 961–975.
- Soheilian, M. *et al.* (2015) “Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial,” *International Ophthalmology*, 35(3), hal. 421–428.
- Tsilimbaris, M., Tsika, C. dan Kymionis, G. D. (2016) “Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery,” *Therapeutics and Clinical Risk Management*, (12), hal. 177–182.
- Usui-Ouchi, A. *et al.* (2021) “Factors affecting a short-term response to anti-vegf therapy in diabetic macular edema,” *Life*, 11(2), hal. 1–9.
- Virgili, G. *et al.* (2015) “Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy,” *Cochrane Database of Systematic Reviews*, 2015(1).
- Virgili, G. *et al.* (2017) “Anti-vascular endothelial growth factor for diabetic macular oedema : a network meta-analysis ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON,” (6).
- Wang, M. *et al.* (2012) “Pharmacokinetic Comparison of Ketorolac After Intracameral ,” *Retina*, 32(10), hal. 2158–2164.
- Wang, M. H., Hsiao, G. dan Al-Shabrawey, M. (2020) “Eicosanoids and oxidative stress in diabetic retinopathy,” *Antioxidants*, 9(6), hal. 1–20.
- Wong, W. M. *et al.* (2020) “Systemic Factors Associated with Treatment Response in Diabetic Macular Edema,” *Journal of Ophthalmology*, 2020.
- World Health Organization (2020) *Strengthening diagnosis and treatment of diabetic retinopathy in the South-East Asia Region*.
- Zhao, X. *et al.* (2017) “Comparison of the efficacy and patients’ tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials,” *PLoS ONE*, 12(3), hal. 1–14.